Vilanterol
Vilanterol is an ultra-long-acting β2-adrenoceptor agonist which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease. The combination is also approved for the treatment of asthma in Canada, Europe, Japan and New Zealand.
Vilanterol is available in following combinations:
- with inhaled corticosteroid fluticasone furoate—fluticasone furoate/vilanterol, Relvar Ellipta )
- with muscarinic antagonist umeclidinium bromide—umeclidinium bromide/vilanterol
- with inhaled corticosteroid fluticasone furoate and muscarinic antagonist umeclidinium bromide—fluticasone furoate/umeclidinium bromide/vilanterol